Pharmaceutical Approach to HIV Protease Inhibitor Atazanavir for Bioavailability Enhancement Based on Solid Dispersion System

Atazanavir (ATV) is a low oral bioavailability (BA) compound and, clinically, is generally coadministrated with ritonavir (RTV), which boosts the oral BA of ATV by inhibiting cytochrome P450 (CYP) 3A, and P-glycoprotein (Pgp) via the same metabolic pathway. However, depending on pharmacokinetic inte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biological & Pharmaceutical Bulletin 2007, Vol.30(4), pp.733-738
Hauptverfasser:	Fukushima, Keizo, Terasaka, Shuichi, Haraya, Kenta, Kodera, Satoshi, Seki, Yuichiro, Wada, Ayako, Ito, Yukako, Shibata, Nobuhito, Sugioka, Nobuyuki, Takada, Kanji
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Animals atazanavir Atazanavir Sulfate Biological Availability Drug Carriers - chemistry Excipients - chemistry Fats - chemistry gelucire 50/13 HIV Infections - blood HIV Infections - drug therapy HIV Infections - virology HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - blood HIV Protease Inhibitors - pharmacokinetics HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Male Oils - chemistry Oligopeptides - administration & dosage Oligopeptides - blood Oligopeptides - pharmacokinetics Oligopeptides - therapeutic use powder X-ray diffraction Powders Pyridines - administration & dosage Pyridines - blood Pyridines - pharmacokinetics Pyridines - therapeutic use Rats Rats, Wistar ritonavir Sodium Dodecyl Sulfate - chemistry sodium lauryl sulfate solid dispersion X-Ray Diffraction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!